Abstract
The establishment of MAO inhibitors in the early 1960s failed, not because of the lack of intended efficacy but because of accompanying side-effects, e.g., hypotension and hypertension, psychic alteration, and hepatotoxicity. With Johnston’s discovery in 1968 of the multiple forms (MAO-A, MAO-B), selective MAO inhibitors could be developed for the first time that considered substrate specificity. Thus, there was hope to reduce the initially observed side-effects. l-Deprenyl (selegiline), synthesized by Ecsery and developed as an antidepressant drug by Knoll, was such a substance. As an antidepressant l-deprenyl did not succeed, but as an anti-Parkinson drug it did [1]. Meanwhile, l-deprenyl has become the “gold standard” of MAO inhibitors. The clinical and theoretical innovations of the last decade have been decisively marked by l-deprenyl since it unites many synergistic biochemical and pharmacological properties. Any new MAO-B inhibitor must have comparable properties since they determine the therapeutic value. Some of these new inhibitors will be reviewed here in comparison to l-deprenyl.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenyl. J Neural Transm, 1975; 36: 303–326.
Riederer P, Jellinger K, Seemann D. Monoamine oxidase and parkinsonism. In: Tipton KF, Dostert P, Strolin-Benedetti M, editors. Monoamine Oxidase and Disease. London: Academic Press, 1984: 403–415.
Birkmayer W, Riederer P, Ambrozi L, Youdim MBH. Implications of combined treatment with “Madopar” and l-deprenyl in Parkinson’s disease — A long-term study. Lancet, 1977; i: 439–443.
Paterson IA, Juorio AV, Boulton AA. Possible mechanism of action of deprenyl in parkinsonism. Lancet, 1992; i: 183.
Paterson I A, Berry MD, Juorio AV. (—) Deprenyl and dopamine transmission: electrophysiological recordings in the rat caudate nucleus. Soc Neurosci Abstr. In press.
Levitt P, Pintar JE, Breakfield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotoninergic neurons. Proc Natl Acad Sci USA, 1982; 79: 6385–6389.
Konradi C, Kornhuber J, Frölich L, Fritze J, Heinsen H, Beckmann H, Schulz E, Riederer P. Demonstration of monoamine oxidase-A and B in the human brainstem by a histochemical technique. Neurosci, 1989; 33: 383–400.
Konradi C, Riederer P, Heinsen H. Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease? In: Przuntek H, Riederer P, editors. Early Diagnosis and Preventive Therapy in Parkinson’s Disease. Key Topics in Brain Research. New York, Vienna: Springer-Verlag, 1989: 243–248.
Melamed E. Chronic levodopa suppresses its own utilization in striatum. In: Rinne UK, Nagatsu T, Horowski R, editors. How to Proceed Today in Treatment. Proceedings International Workshop Berlin Parkinson’s Disease. Medicom Europe, 1991: 206–215.
Rinne UK. Early use of dopamine agonist in the treatment of Parkinson’s disease. In: Rinne UK, Nagatsu T, Horowski R, editors. How to Proceed Today in Treatment. Proceedings International Workshop Berlin Parkinson’s Disease. Medicom Europe, 1991: 326–336.
Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson’s disease. In: Yahr MD, Bergmann KJ, editors. Advances in Neurology. New York: Raven Press, 1986: 119–125.
Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol, 1989; 26: 689–690.
Fornstedt B, Brun A, Rosengren E, Carlsson A. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm [PD Sect], 1989; 1: 279–295.
Gerlach M, Riederer P, Youdim MBH. The molecular pharmacology of l-deprenyl. Europ J Pharmacol — Mol Pharmacol Sect, 1992; 226: 97–108.
Jarman J, Glover V, Sandler M, Turjanski N, Stern G. Platelet monoamine oxidase B activity in Parkinson’s disease: A re-evaluation. J Neural Transm [PDSect]. In press.
Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Devel, 1988; 46: 237–262.
Clow A, Hussain T, Glover V, Sandler M, Dexter DT, Walker M. (-)-Deprenyl can induce soluble superoxide dismutase in rat striata. J Neural Transm, 1991; 86: 77–80.
Ceballos I, Lafon M, Javoy Agid F, Hirsch E, Nicole A, Simet P, Agid Y. Superoxide dismutase and Parkinson’s disease. Lancet, 1990; i: 1035–1036.
Knoll J, Dallo J, Yen TT. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci, 1989; 45: 525–531.
Milgrana NW, Racine RJ, Nellis P, Mendonca A, Ivy GO. Maintenance on l-deprenyl prolongs life in aged male rats. Life Sci, 1990; 47: 415–420.
Aquilonius SM, Jossan SS, Ekblom JG, Askmark H, Gillberg PG. Increased binding of l-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography. J Neural Transm [Gen Sect]. 1992; 89: 111–122.
Paterson IA, Juorio AV, Boulton AA. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem, 1990; 55: 1827.
Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D. Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (—)deprenyl administration. J Neural Transm, 1978; 43: 271–277.
Elsworth JD, Sandler M, Lees AJ, Ward C, Stern GM. The contribution of amphetamine metabolites of (—)-deprenyl to its antiparkinsonian properties. J Neural Transm, 1982; 54: 105–110.
Birkmayer W, Riederer P. Die Parkinson-Krankheit. Biochemie, Klinik, Therapie, 2nd ed. Vienna, New York: Springer Verlag, 1985.
Rinne JO, Röyttä M, Paljärvi L, Rummukainen J, Rinne UK. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson’s disease. Neurol, 1991; 41: 859–861.
Davis GC, Williams AC, Markey SP, Ebert MH, Calne ED, Reichert C, Kopin IJ. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res, 1979; 1: 249–254.
Burns RS, Chiuen CC, Markey SP, Ebert MH, Jacobowitz D, Kopin I. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA, 1983; 80: 4544–4551.
Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature, 1984; 311: 467–469.
Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem, 1986; 46: 1359–1365.
Gerlach M, Riederer P, Przuntek H, Youdim MBH. MPTP mechanisms of neurotoxicity and their implications for Parkinson’s disease. Europ J Pharmacol — Mol Pharmacol Sect, 1991; 208: 273–286.
Barbeau A, Roy M, Cloutier T, Plasse L, Paris S. Environmental and genetic factors in the etiology of Parkinson’s disease. In: Yahr MD, Bergmann KJ, editors. Advances in Neurology. New York: Raven Press, 1986: 299–306.
Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res, 1991; 30: 666–672.
Heikkila RE, Cohen G. Further studies on generation of hydrogen peroxide by 6-hy-droxydopamine: potentiation by ascorbic acid. Mol Pharmacol, 1972; 8: 241.
Sachs CH, Jonsson G. Mechanism of action of 6-hydroxydopamine. Pharmacol 1975; 24: 1.
Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quiñones. Mol Pharmacol, 1978; 14: 333–343.
Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH. The iron chelator desferoxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem, 1991; 56: 1441–1447.
Knoll J. The possible mechanism of action of (-)deprenyl in Parkinson’s disease. J Neural Transm, 1978; 43: 177–198.
Knoll J. Striatal dopamine, ageing and (-)deprenyl. Jugoslav Physiol Pharmacol Acta, 1986; 22: 261–273.
Knoll J. R-(-)-deprenyl (selegiline, Movergan®) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm [Suppl], 1987; 25: 45–66.
Carillo MC, Kanai S, Nokubu M, Kitani K. (—)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sc, 1991; 48: 517–521.
Clow A, Hussain T, Glover V, Sandler M, Walker M, Dexter D. Pergolide can induce soluble superoxide dismutase in rat striata. J Neural Transm [Gen Sect]. 1991; 86: 77–80.
Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston JW. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Europ J Pharmacol, 1990; 184: 119–126.
Birkmayer W, Knoll J, Riederer P, Youdim MBH. (—)Deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Modern Problems of Pharmacopsychiatry, Vol 19. Basel: Karger, 1983: 170–176.
Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson’s disease: a long-term study. J Neural Transm, 1985; 64: 113–117.
Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science, 1989; 245: 519–522.
DATATOP (Parkinson Study Group). Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med, 1989; 321: 1364–1371.
Landau WM. Clinical neuromythology IX. Pyramid scale in the bucket shop: DATATOP bottoms out. Neurol, 1990; 40: 1337–1339.
Green R, Youdim MBH. Use of a behavioral model to study the action of monoamine oxidase inhibition in vivo. In: Monoamine Oxidase and Its Inhibition (Ciba Foundation Symposium 39). Amsterdam: Elsevier, 1976: 231–246.
Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, et al. Deprenyl administration in man; a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacol, 1978; 57: 33–38.
Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra in Parkinson’s disease. Neurosci Lett. 1992; 142: 128–130.
Olney JW, Price MT, Labruyere J, Salles KS, Friedrich G, Mueller M, et al. Anti-parkin- sonian agents are pheneyelidine agonists and N-methyl-aspartate antagonists. Europ J Pharmacol, 1987; 142: 319–325.
Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Europ J Pharmacol, 1989; 166: 589–590.
Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P. Effects of the 1-amino- adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Europ J Pharmacol — Mol Pharmacol Sect, 1991; 206: 297–300.
Youdim MBH, Ben-Shachar D, Riederer P. The role of monoamine oxidase, iron-melanin interaction and intracellular calcium in Parkinson’s disease. J Neural Transm [Suppl], 1990; 32: 239.
Furukawa S, Shinoda I, Furukawa Y. Regulatory mechanisms of nerve growth factor synthesis in vitro. Human Cell, 1989; 6 (2): 137–142.
Finberg JPM, Sabbagh A, Youdim MBH. Pharmacology of selective propargyl “suicide” inhibitors of monoamine oxidase. In: Usdin E, Sourkes TL, Youdim MBH, editors. Enzymes and Neurotransmitters in Mental Disease. Chichester: Wiley, 1980: 205.
Kalir A, Sabbagh A, Youdim MBH. Selective acetylenic “suicide” and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol, 1981; 73: 55–62.
Da Prada M, Kettler R, Keller HH, Cesura Am, Richard JG, Marti JS et al. From moclobemide to Ro 19–6327 and Ro 41–1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl], 1990; 29: 279–292.
Zerika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG. MDL 72974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson’s disease. J Neural Transm (PD Sect.), 1989; 1: 243–254.
Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM et al. l-(-)Deprenyl in Alzheimer’s disease. Arch Gen Psychiat, 1987a; 44: 427–433.
Tariot PN, Sunderland T, Weingartner H, Murphy DL, Welkowitz JA, Thompson K et al. Cognitive effect of l-deprenyl in Alzheimer disease. Psychopharmacol, 1987b; 91: 489–495.
Tariot PN, Sunderland T, Cohen RM, Newhouse PA, Mueller EA, Murphy DL. Tranylcypromine compared with l-deprenyl in Alzheimer disease. J Clin Psychopharma- col, 1988; 8: 23–27.
Martini E, Pataky J, Szilagyi K, Venter V. Brief information on an early phase-II study with (-)deprenyl in demented patients. Pharmacopsychiat, 1987; 20: 256–257.
Piccinin GL, Finali GC, Piccirilli M. Neuropsychological effects of l-deprenyl in Alzheimer’s type dementia. Clin Neuropharmacol, 1990; 13: 147–163.
Mangoni A, Grassi MP, Frattoli L, Piolti R, Bassi S, Motta A et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol, 1991; 31: 100–107.
Goad DL, Davis CM, Leim P, Fuselier CC, McCormack JR, Olsen KM. The use of selegiline in Alzheimer’s patients with behavior problems. J Clin Psychiat, 1991; 52: 342–345.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Basel AG
About this chapter
Cite this chapter
Riederer, P., Youdim, M.B.H. (1993). The Therapeutic Place and Value of Present and Future MAO-B Inhibitors — l-Deprenyl as the Gold Standard. In: Szelenyi, I. (eds) Inhibitors of Monoamine Oxidase B. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-6348-3_18
Download citation
DOI: https://doi.org/10.1007/978-3-0348-6348-3_18
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-6349-0
Online ISBN: 978-3-0348-6348-3
eBook Packages: Springer Book Archive